A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.

Fiche publication

Date publication

avril 2022

Journal

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GAIDDON Christian

Tous les auteurs :
Miller JJ, Kwan K, Gaiddon C, Storr T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35488931

Résumé

Metal ion dysregulation has been implicated in a number of diseases from neurodegeneration to cancer. While defective metal ion transport mechanisms are known to cause specific diseases of genetic origin, the role of metal dysregulation in many diseases has yet to be elucidated due to the complicated function (both good and bad!) of metal ions in the body. A breakdown in metal ion speciation can manifest in several ways from increased reactive oxygen species (ROS) generation to an increase in protein misfolding and aggregation. In this review, we will discuss the role of Zn in the proper function of the p53 protein in cancer. The p53 protein plays a critical role in the prevention of genome mutations via initiation of apoptosis, DNA repair, cell cycle arrest, anti-angiogenesis, and senescence pathways to avoid propagation of damaged cells. p53 is the most frequently mutated protein in cancer and almost all cancers exhibit malfunction along the p53 pathway. Thus, there has been considerable effort dedicated to restoring normal p53 expression and activity to mutant p53. This includes understanding the relative populations of the Zn-bound and Zn-free p53 in wild-type and mutant forms, and the development of metallochaperones to re-populate the Zn binding site to restore mutant p53 activity. Parallels will be made to the development of multifunctional metal binding agents for modulating the aggregation of the amyloid-beta peptide in Alzheimer's Disease (AD).